Compugen Ltd.

CGEN

Healthcare Biotechnology

Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024.

Revenue
+107.0%
EPS
+12.5%
Free cash flow
−155.4%

Quarter to June 2026, against a year earlier

1.96 0.04 +2.08%
Market cap
$185.7M
P/E
5.2×
Fwd P/E
n/m
Dividend yield
—
F-score
7/9
ROIC
0.00%
Net debt / EBITDA
−4.7×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
5.63 5.76 4.14 0.00

+8 more quarters

P/S ratio
2.74 2.77 1.96 19.92
P/FCF ratio
5.06 1.98 1.41 3.08
P/Operating CF
(9.23) 6.37 4.52 (7.41)
P/B ratio
2.28 1.96 1.39 1.34
EV/Sales
1.04 0.91 (0.04) 7.45
EV/EBITDA
2.55 2.16 0.00 0.00
EV/FCF
1.93 0.65 (0.03) 1.15
Current Ratio
5.72 6.23 6.56 4.38
Net Debt/EBITDA
14.18 14.97 (2.60) 10.91
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
17.76% 17.37% 24.18% (20.41%)
Free Cash Flow Yield
19.77% 50.49% 71.14% 32.42%
Free Cash Flow per Share
(0.23) 0.00 0.34 0.00
Book value per Share
0.94 1.01 1.10 0.47
Free Cash Flow
(21.98) — 31.33 —
EV/EBIT
2.55 2.16 0.00 0.00
Other line items

Show all line items

Columns are period end dates